What this opportunity is
The Department of Defense is seeking information from product developers for the Vaccine Acceleration by Modular Progression (VAMP) program, focused on creating prophylactic platform technologies for medical countermeasures against chemical, biological, radiological, and nuclear threats. This opportunity is open to all businesses, as there is no set-aside, and it is classified under NAICS 541715. Interested parties should note that this is a Special Notice, indicating that it is primarily for information gathering rather than a formal solicitation, which may require tracking for future bidding opportunities.
Analysis by Mindy, grounded in the SAM.gov notice.
Description
1
APPENDIX 2
PROJECT DESCRIPTION/STATEMENT OF OBJECTIVES
PROJECT TITLE
Vaccine Acceleration by Modular Progression (VAMP) - Prophylactic Platform Technology
Medical Countermeasures (MCMs) Against Chemical, Biological, Radiological, and Nuclear
(CBRN) Threats
BACKGROUND/DESCRIPTION
The Portfolio Management Executive for Chemical, Biological, Radiological, and Nuclear
Defense (PME CBRND), Joint Program Manager – CBRN Medical (JPM-M) Accelerated Defense
Pharmaceuticals (ADP) Product Office, is requesting from product developers the design,
manufacture, non-clinical and clinical testing of advanced platform technology for prophylaxis
against one or more specific CBRN threats of concern. The Government is interested in approaches
that will support the development of prophylactic platform technology using traditional or non-
traditional administration as well as immune modulating approaches.
The VAMP program evaluates platform technologies against disease/injury caused by CBRN
threats in appropriate animal models and human clinical trials for safety, immune response, and
effectiveness while using data-driven decision and processes to bridge capability gaps for the
warfighter. The goal of the program is to expedite the development of these prophylactic MCMs
through a Phase I or Phase II clinical trial. To achieve this, the VAMP program utilizes a modular
approach incorporating Go/No-Go checkpoints at each applicable non-clinical, clinical, CMC and
regulatory phases to facilitate generation of an Investigational New Drug Application, end of Phase
1, or end of Phase 2 data packages supporting further advancement as warranted.
As part of the current MCM environment to protect against CBRN threat agents listed in Appendix
1, the Government is interested in furthering the development of prototype candidates using either
traditional (intramuscular injection) or alternative routes of administration (i.e., microneedles,
intranasal, etc., and defined below as non-traditional administration). In addition, MCMs that can
enhance and modulate the immune system (biological response modifiers) expand the
Government’s toolbox of MCMs while building the warfighter’s bio-armor.
To be eligible for funding, Offerors shall have a demonstrated, successful history of designing,
manufacturing, and clinical testing of prophylactic MCM platform as well as experience working
with the U.S. Food and Drug Administration (FDA). Additionally, Offerors will have expertise in
all aspects of platform manufacturing under current Good Manufacturing Practices (cGMP) and
prophylactic platform development with the intent to obtain licensure. Pending the outcome of
program modules, the Government may consider further development and/or procurement of
successful prophylaxes under a separate agreement.
PROGRAM OBJECTIVES
1) Performance Objectives
a. Program Objectives
-- 1 of 8 --
2
The project objectives include design, development, non-clinical testing,
manufacturing and human clinical trials for mature prophylactic platform technologies.
The project will result in successful prototype candidates that are safe to administer to
humans to protect against Department of War (DoW) priority threats; work can be
targeted to a threat or threats which could pivot and expand to other threat agents of
interest upon a negotiated mutual modification.
This includes complete product development and required stage-appropriate studies of
these candidates against CBRN threats in Appendix 1. First-in-human products should
include submission of an Investigational New Drug (IND), and all studies necessary
through a Phase I clinical trial, as soon as possible.
The prophylactic platform candidates, utilizing a traditional or non-traditional route of
administration developed for this project, must target at least one of the CBRN threats
of interest to the Government (preferably broad spectrum). Specifically, the Offeror is
responsible for:
Module 1: Design a prophylactic medical product candidate targeting one or more
CBRN threats listed in Appendix 1.
• Design a prophylactic medical product on manufacturable platform technology
and formulate final candidate (prototype product) for clinical evaluation – This
includes all methods and assays associated with the optimization, selection, and
evaluation of an immunogenic platform construct, suitable for cGMP
manufacture at development stage- appropriate levels, and human studies.
• All aspects of construction and formulation of the platform candidate for
delivery – Traditional delivery formulation methods/processes shall be
supported by historical safety and immunogenicity data and align with selected
mode of delivery. Non-traditional routes of administration shall be supported
by technical testing and/or formulation for specific non-traditional route of
administration, as applicable.
• Acceptable modes of delivery include intramuscular injection and needle-free
delivery (such as transdermal/microneedle skin patch, intranasal formulation,
etc.).
• Demonstrate established platform technology cGMP manufacturing, as needed.
• Development of any lot release testing needed for cGMP production.
• Stability testing of the prototype product to support human clinical use.
Module 2: Animal studies, including toxicity and efficacy, as applicable. Initiated
upon completion of prototype product design and formulation.
• Perform pre-clinical studies to support submission of an IND in the effort for
the prototype product.
• Develop and establish stage-appropriate (i.e., qualified vs. validated) assays and
methods suitable for intended use to measure the immunogenicity of the
prototype product in humans and animals (i.e., non-human primates)
demonstrated suitable for bridging animal efficacy outcomes to human clinical
-- 2 of 8 --
3
trial immunogenicity data. All immune assays to measure clinical endpoints are
expected to be well-controlled (i.e., qualified or validated based on the phase of
clinical study) prior to clinical…
Source: SAM.gov, as posted. Verify the current solicitation before responding.